See more : Mobi724 Global Solutions Inc. (MOBIF) Income Statement Analysis – Financial Results
Complete financial analysis of Longboard Pharmaceuticals, Inc. (LBPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Longboard Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Via Renewables, Inc. (VIASP) Income Statement Analysis – Financial Results
- L&F Acquisition Corp. (LNFA) Income Statement Analysis – Financial Results
- Arch Resources, Inc. (ARCH) Income Statement Analysis – Financial Results
- Unilever PLC (UNI2.DE) Income Statement Analysis – Financial Results
- SmileDirectClub, Inc. (SDCCQ) Income Statement Analysis – Financial Results
Longboard Pharmaceuticals, Inc. (LBPH)
About Longboard Pharmaceuticals, Inc.
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 5.00K | 5.00K | 1.00K | 0.00 |
| Gross Profit | -5.00K | -5.00K | -1.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 43.75M | 34.64M | 19.77M | 4.63M |
| General & Administrative | 13.01M | 10.16M | 8.07M | 9.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.01M | 10.16M | 8.07M | 9.77M |
| Other Expenses | 0.00 | 16.00K | -22.00K | 0.00 |
| Operating Expenses | 56.76M | 44.80M | 27.84M | 14.40M |
| Cost & Expenses | 56.76M | 44.80M | 27.84M | 14.40M |
| Interest Income | 2.41M | 837.00K | 64.00K | 0.00 |
| Interest Expense | 0.00 | 837.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 5.00K | 5.00K | 1.00K | 7.00M |
| EBITDA | -56.75M | -44.79M | -27.84M | -14.40M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -56.76M | -44.80M | -27.84M | -14.40M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.34M | 853.00K | 42.00K | 0.00 |
| Income Before Tax | -54.42M | -43.95M | -27.80M | -14.40M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -853.00K | -64.00K | -14.40K |
| Net Income | -54.42M | -43.09M | -27.73M | -14.40M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.39 | -2.51 | -1.62 | -0.82 |
| EPS Diluted | -2.39 | -2.51 | -1.62 | -0.82 |
| Weighted Avg Shares Out | 22.73M | 17.15M | 17.07M | 17.67M |
| Weighted Avg Shares Out (Dil) | 22.73M | 17.15M | 17.07M | 17.67M |
Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the initiation of a Phase 1 randomized, double-blind, placebo-controlled, SAD clinical study of LP659. LP659...
Down -25.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Longboard Pharmaceuticals, Inc. (LBPH)
Longboard Pharmaceuticals, Inc. (LBPH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal...
Longboard Pharmaceuticals' Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will present data for LP352, a novel, highly selective investigational treatment in development...
Wall Street Analysts Believe Longboard Pharmaceuticals, Inc. (LBPH) Could Rally 262.45%: Here's is How to Trade
The consensus price target hints at a 262.5% upside potential for Longboard Pharmaceuticals, Inc. (LBPH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness...
Longboard Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to one new employee. The Compensation Committee of the Board...
Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2023....
Longboard Pharmaceuticals to Present at Three Upcoming Investor Conferences in November
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior management team will present at three upcoming investor conferences in...
Longboard Pharmaceuticals Announces Speakers for Investor & Analyst Event in New York on October 11, 2023
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the speakers for its upcoming Investor & Analyst Event focused on the Developmental and Epileptic...
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on October 11, 2023
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host an Investor & Analyst Event focused on the Developmental and Epileptic...
Longboard Pharmaceuticals to Participate in Three Upcoming Investor Conferences
LA JOLLA, Calif.--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior management team will participate in three upcoming investor conferences in...
Source: https://incomestatements.info
Category: Stock Reports